Steward Partners Investment Advisory’s Recursion Pharmaceuticals RXRX Stock Holding History

Steward Partners Investment Advisory’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$124K	Buy	40,264 +900	+2%	+$3.48K	﹤0.01%	2260
2025 Q4	$161K	Sell	39,364 -14,500	-27%	-$71.8K	﹤0.01%	2032
2025 Q3	$263K	Buy	53,864 +2,999	+6%	+$15.8K	﹤0.01%	1726
2025 Q2	$257K	Hold	50,865	–	–	﹤0.01%	1635
2025 Q1	$269K	Buy	50,865 +36,300	+249%	+$265K	﹤0.01%	1502
2024 Q4	$98.5K	Buy	14,565 +9,982	+218%	+$67.1K	﹤0.01%	1993
2024 Q3	$30.2K	Buy	4,583 +3,000	+190%	+$21.5K	﹤0.01%	2468
2024 Q2	$11.9K	Buy	1,583 +1,000	+172%	+$8.72K	﹤0.01%	2748
2024 Q1	$5.81K	Buy	583 +83	+17%	+$924	﹤0.01%	2997
2023 Q4	$4.93K	Buy	+500	New	+$3.56K	﹤0.01%	2964

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Steward Partners Investment Advisory's RXRX Position: Q1 2026 in Review

Steward Partners Investment Advisory increased its Recursion Pharmaceuticals (RXRX) stake by 2.3% in Q1 2026, buying an estimated $3.48K and bringing the position to 40,264 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #2260.

Steward Partners Investment Advisory first reported a position in RXRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $269K in Q1 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Steward Partners Investment Advisory held 40,264 shares of Recursion Pharmaceuticals worth $124K as of Q1 2026.
Steward Partners Investment Advisory bought 900 Recursion Pharmaceuticals shares in Q1 2026, an estimated $3.48K.
Recursion Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q1 2026, its #2260 holding.
Steward Partners Investment Advisory first reported a position in Recursion Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
Steward Partners Investment Advisory's Recursion Pharmaceuticals position peaked at $269K in Q1 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q1 2026, filed 8 May 2026.